High content screening of induced pluripotent stem cells as a model to study human brain diseases
- Daniel Rodrigues Furtado1
© Furtado; licensee BioMed Central Ltd. 2014
Published: 1 October 2014
Induced pluripotent stem (iPS) cells differentiated into neural progenitor cells (NPCs) hold great potential as a tool for modeling brain disease. When coupled to high content screening (HCS), NPCs may become a powerful tool for drug discovery. One of the goals of the new Molecular Biology and Cell Reprogramming, headed by Dr. Stevens Rehen at the D'Or Institute for Research and Education, is to develop a high content screening (HCS) strategy to study human brain diseases through the use of iPS. As a starting point, the effects of psychoactive drugs were characterized in NPCs by using HCS. Thousands of cells and single mitochondria were analyzed individually by HCS software and submitted to several sequences of morphometric analyses and fluorescence quantification. Morphological and functional alterations in mitochondria, which can be linked to energetic metabolism failure, a key trigger to abnormal neuronal development, were also observed. I will discuss the impact of HCS technology applied to neural stem cells as an attractive platform to drug discovery, cytotoxicity assessment and disease modeling.
Supported by: BNDES, CNPq, FINEP, CAPES and FAPERJ.
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.